← Back to Insights
Compliance

PIPEDA and AI: 5 things pharmaceutical teams get wrong

Pharma teams using AI tools risk PIPEDA violations without knowing it. Five common mistakes, and why Canadian AI changes the risk.

By Augure·
a stethoscope, pills, and a shopping cart on a blue background

Yes, PIPEDA applies to your AI tools, even the free ones your team downloaded without asking IT. PIPEDA is the federal privacy law, and it covers any personal information your company touches during business, including patient data, trial records, and adverse event reports fed into a chatbot.

Pharmaceutical teams handle some of the most sensitive data in the country. Clinical trial participants. Patient support programs. Adverse event reports with names attached. When that data goes into an AI tool, the privacy rules don't pause because the tool is convenient. Here are five mistakes we see pharma teams make, and what a Canadian AI platform changes about each one.

Mistake one: assuming the AI vendor is "just a tool"

Your AI chatbot is not neutral. The moment someone pastes a patient complaint or a trial site report into a chat window, that data leaves your building. It might sit on a server in another country. It might get used to train a model you'll never see.

Under PIPEDA, you're still responsible for that data, no matter whose software touched it. If a vendor mishandles it, the accountability comes back to you. This is the mistake that causes the most damage, because it's invisible until something goes wrong.

What makes it worse is that your vendor contract rarely tells you this plainly. Most AI terms of service are written for a general consumer, not a pharma compliance officer, so the data-handling clause sits buried on page nine next to the refund policy. If you've never read that clause, assume it favours the vendor.

Where does the data actually go?

Most popular AI tools are built by American companies. That means your data can be pulled into US systems, subject to US law, including laws that let US authorities request access to data held by US-controlled providers. For pharma, where trial data and patient records carry extra sensitivity, this matters more than it does for a marketing team writing ad copy.

This is where a Canadian AI platform earns its keep. Augure is a Canadian company operating under Canadian law. Customer data is stored in Canada. AI inference runs on Canadian infrastructure, with vetted European partners handling some model tiers and failover, never on US servers. Augure has no US corporate parent and no US investors, so customer conversations and documents aren't handled by providers under US jurisdiction.

That doesn't mean zero cross-border activity. Payment processing and email delivery still touch US systems, because that's how card networks and email work. Augure discloses this plainly in its privacy policy instead of pretending it doesn't happen. For a privacy risk assessment under Quebec's law or PIPEDA, knowing exactly which flows exist beats a vendor telling you everything stays put when it doesn't.

A skeptical reader might ask: doesn't every vendor claim this kind of thing? Fair question. The difference is whether the claim can be checked against a named sub-processor list, not just a marketing page. Ask any vendor, including Augure, to show you that list before you sign.

Mistake two: no consent trail for AI-assisted work

PIPEDA requires meaningful consent before you collect, use, or disclose personal information. Teams often get consent for the original purpose, like running a clinical trial, but never update it to cover "and then we fed your file into an AI summarizer."

If your consent forms were written in 2019, they almost certainly don't cover this. Check them. A short addendum covering AI-assisted processing is cheap insurance.

Updating consent isn't just a legal formality, either. It's a conversation with your research ethics board, because most boards treat a change in data processing as a protocol amendment, not a footnote. Budget a few weeks, not a few days, if your trial is still active.

Mistake three: treating "de-identified" as "safe"

Pharma teams love the word de-identified. It feels like a shield. But badly de-identified data, especially small trial cohorts or rare-disease populations, can often be re-identified by cross-referencing other public data. An AI model with a large enough context window and a curious user can sometimes do this without even trying hard.

Canada's privacy regulator has flagged re-identification risk repeatedly over the past several years. The rule of thumb: if removing names took you fifteen minutes, that data isn't as anonymous as it feels.

The exception worth knowing: large, well-mixed datasets, like aggregate adverse-event counts across thousands of patients, carry much lower re-identification risk than a trial of twelve people with a rare condition. Treat cohort size as the first question, not the method you used to strip names.

Mistake four: letting shadow AI tools pile up

Someone on the regulatory affairs team starts using a free AI tool for drafting summaries. Someone in medical affairs uses a different one for literature reviews. Nobody in IT knows either exists.

This is the most common failure point we hear about from compliance leads. A few things to check before this spirals:

  • Which teams are using AI tools right now, and for what tasks
  • Whether any of those tools touch patient data, trial data, or adverse event reports
  • Where each tool stores and processes data, and whether that's documented anywhere

Most companies find the answer to that third question is "we don't actually know." That's the gap to close first.

Mistake five: no plan for a breach involving AI

If an AI tool leaks data, who do you call? What do you tell Health Canada, the research ethics board, or the trial sponsor? Most pharma privacy policies were written before generative AI existed and don't mention it at all.

PIPEDA requires you to report breaches that create a real risk of significant harm, and to keep records of every breach you assess, even the ones you decide not to report. An AI-specific breach, like a chatbot surfacing one patient's data in response to another user's question, needs its own line in that plan.

A privacy policy that doesn't mention AI is already out of date.

What does a Canadian AI platform actually change here?

It doesn't make you compliant by itself. No vendor can promise that, and anyone who does is selling you something. What it changes is the baseline risk you're building on top of.

Augure starts free, with a daily compute allowance and basic document search, which is enough for a small regulatory affairs team to pilot. Paid plans start at $20 a month for priority models and persistent memory, scaling to $80 a month for teams running deep research across trial literature and compliance documents. For legal and contract review specifically, Augure Legal handles NDA triage and compliance checks starting at $149 a month.

All of it runs on Canadian infrastructure, with Quebec's privacy law and PIPEDA considered from the start, not bolted on afterward. Customer data is never used to train models.

What to do this week

  1. List every AI tool your team is currently using, including the free ones nobody officially approved.
  2. Pull your consent forms and check whether any mention AI-assisted processing. If not, draft a one-paragraph addendum.
  3. Ask your privacy lead whether the breach response plan says anything about AI tools. If it's silent, that's this week's fix.

Start with Augure's free plan at augureai.ca and see what Canadian AI looks like before your next trial report needs summarizing.

Where this comes from: PIPEDA defines a reportable breach as one creating "a real risk of significant harm" (s. 10.1).

A

About Augure

Augure is a sovereign AI platform for regulated Canadian organizations. Chat, knowledge base, and compliance tools — all running on Canadian infrastructure.

Ready to try sovereign AI?

Start free. No credit card required.

Get Started